1.10
+0.05(+4.76%)
Currency In USD
| Previous Close | 1.05 |
| Open | 1.05 |
| Day High | 1.12 |
| Day Low | 1.05 |
| 52-Week High | 5.51 |
| 52-Week Low | 0.98 |
| Volume | 794,496 |
| Average Volume | 533,877 |
| Market Cap | 93.53M |
| PE | -0.6 |
| EPS | -1.83 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 2.4 |
| Change | 0.05 |
If you invested $1000 in Century Therapeutics, Inc. (IPSC) since IPO date, it would be worth $48.18 as of December 21, 2024 at a share price of $1.1. Whereas If you bought $1000 worth of Century Therapeutics, Inc. (IPSC) shares 2 years ago, it would be worth $180.62 as of December 21, 2024 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announc
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire Inc.
Nov 05, 2024 2:05 PM GMT
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favora
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 05, 2024 2:00 PM GMT
– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate functi